Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences.

Calabrò, Luana; Ceresoli, Giovanni Luca; D'Incecco, Armida; Scherpereel, Arnaud; Aerts, Joachim; Maio, Michele

Calabrò, Luana; Ceresoli, Giovanni Luca; D'Incecco, Armida; Scherpereel, Arnaud; Aerts, Joachim; Maio, Michele.

Afiliação

Calabrò L; Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy. Electronic address: l.calabro@ao-siena.toscana.it.
Ceresoli GL; Thoracic & GU Oncology Unit Department of Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy.
D'Incecco A; Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.
Scherpereel A; Pulmonary and Thoracic Oncology, CHU de Lille, Univ Lille, Mesoclin Network, F59000 Lille, France.
Aerts J; Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Maio M; Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.

Cytokine Growth Factor Rev ; 36: 25-31, 2017 08.

Article em En | MEDLINE | ID: mdl-28736182

ABSTRACT

ABSTRACT

Treatment with immune-checkpoint blocking monoclonal antibody (mAb) is demonstrating a significant efficacy in different tumor types. Here, we discuss the impact of this promising approach in malignant mesothelioma (MM), a still dreadful disease in which medical treatment has been set on platinum based chemotherapy for decades with unsatisfactory results.

Assuntos

Anticorpos Monoclonais/uso terapêutico; Imunoterapia/métodos; Neoplasias Pulmonares/imunologia; Neoplasias Pulmonares/terapia; Mesotelioma/imunologia; Mesotelioma/terapia; Anticorpos Monoclonais/administração & dosagem; Antígeno B7-H1/antagonistas & inibidores; Antígeno B7-H1/imunologia; Antígeno CTLA-4/antagonistas & inibidores; Antígeno CTLA-4/imunologia; Humanos; Mesotelioma Maligno; Receptor de Morte Celular Programada 1/antagonistas & inibidores; Receptor de Morte Celular Programada 1/imunologia

Palavras-chave

CTLA-4; Immune-checkpoint; Immunotherapy; Mesothelioma; PD-1; PD-L1

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia / Neoplasias Pulmonares / Mesotelioma / Anticorpos Monoclonais Limite: Humans Idioma: En Revista: Cytokine Growth Factor Rev Assunto da revista: ALERGIA E IMUNOLOGIA / BIOQUIMICA Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google